-
Sector Analysis
Insomnia Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
Insomnia Market Report Overview The Insomnia market across the 7MM (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan) was valued at $3.2 billion in 2022. Steady growth is anticipated at a CAGR of more than 2% from 2022 to 2032, due to the launch of four novel pipeline agents - Hetlioz, SM-1, vornorexant, and sunobinop. The insomnia market research report offers an overview of insomnia, including its epidemiology, symptoms, diagnosis, and disease management. The report offers key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tradipitant in Functional (Non Ulcer) Dyspepsia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tradipitant in Functional (Non Ulcer) Dyspepsia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tradipitant in Functional (Non Ulcer) Dyspepsia Drug Details: Tradipitant (VLY-686,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tradipitant in Gastroparesis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tradipitant in Gastroparesis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tradipitant in Gastroparesis Drug Details: Tradipitant (VLY-686, LY-686017) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Docetaxel Albumin Bound in Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Docetaxel Albumin Bound in Ovarian Cancer Drug Details: Docetaxel albumin bound is under development for...
-
Product Insights
Gastroparesis – Drugs In Development, 2023
Global Markets Direct’s, ‘Gastroparesis - Drugs In Development, 2023’, provides an overview of the Gastroparesis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gastroparesis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Dyspepsia (Indigestion) – Drugs In Development, 2023
Global Markets Direct’s, ‘Dyspepsia (Indigestion) - Drugs In Development, 2023’, provides an overview of the Dyspepsia (Indigestion) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dyspepsia (Indigestion), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Functional (Non Ulcer) Dyspepsia – Drugs In Development, 2023
Global Markets Direct’s, ‘Functional (Non Ulcer) Dyspepsia - Drugs In Development, 2023’, provides an overview of the Functional (Non Ulcer) Dyspepsia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Functional (Non Ulcer) Dyspepsia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Cholera – Drugs In Development, 2023
Global Markets Direct’s, ‘Cholera - Drugs In Development, 2023’, provides an overview of the Cholera pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cholera, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...